Health · 1 sources covering this

STAT+: Verastem’s KRAS inhibitor shows promise in pancreatic cancer

Verastem Oncology reports encouraging early results for its KRAS G12D inhibitor, which it’s studying in more than 200 patients with advanced solid tumors like metastatic pancreatic ductal adenocarcinoma and non-small…

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·1h ago
STAT+: Verastem’s KRAS inhibitor shows promise in pancreatic cancer
Verastem Oncology reports encouraging early results for its KRAS G12D inhibitor, which it’s studying in more than 200 patients with advanced solid tumors like metastatic pancreatic ductal adenocarcinoma and non-small…
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/f643568cb1c13ce18381d0c108a8b9ddae6da67d"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Verastem&#8217;s KRAS inhibitor shows promise in pancreatic cancer"></iframe>

STAT+: Verastem’s KRAS inhibitor shows promise in pancreatic cancer

How 1 sources are covering this

STAT+: Verastem’s KRAS inhibitor shows promise in pancreatic cancer

More from Health

STAT+: Former FDA commissioners Califf, Gottlieb, Sharpless lay into current HHS leadership

After a melanoma diagnosis, mRNA cancer vaccine delivered a patient hope — and a path forward

STAT+: Pharmalittle: We’re reading about former FDA head calling DOGE a ‘disaster,’ an AstraZeneca AI deal, and more

STAT+: ‘AI sandboxes’ are all the rage. Advocates scramble to control their future

Reader

Trust & legal

Across the network

How 1 sources are covering this

STAT+: Verastem&#8217;s KRAS inhibitor shows promise in pancreatic cancer

More from Health

STAT+: Former FDA commissioners Califf, Gottlieb, Sharpless lay into current HHS leadership

After a melanoma diagnosis, mRNA cancer vaccine delivered a patient hope — and a path forward

STAT+: Pharmalittle: We&#8217;re reading about former FDA head calling DOGE a &#8216;disaster,&#8217; an AstraZeneca AI deal, and more

STAT+: &#8216;AI sandboxes&#8217; are all the rage. Advocates scramble to control their future

Reader

Trust & legal

Across the network

STAT+: Verastem’s KRAS inhibitor shows promise in pancreatic cancer

STAT+: Pharmalittle: We’re reading about former FDA head calling DOGE a ‘disaster,’ an AstraZeneca AI deal, and more

STAT+: ‘AI sandboxes’ are all the rage. Advocates scramble to control their future